-
Evaluating the Cost-Effectiveness of High-Dose Influenza Vaccination for Adults Aged 60 Years and Older in Austria
Sep 9, 2025, 16:22 PM -
Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis
Sep 9, 2025, 16:22 PM -
Do We Need to Measure Social Impact of Innovative Drugs?
Sep 9, 2025, 16:22 PM -
Economic Evaluations of First-Line Non-Small Cell Lung Cancer Therapies: A Systematic Review With Focus on PD-L1 Subgroups
Sep 9, 2025, 16:22 PM -
Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy
Sep 9, 2025, 16:22 PM -
What Tips the Scale Toward Reimbursement? A Dutch-led Comparison of Pharmacoeconomic Evaluations Across the Netherlands, Sweden, and the United Kingdom
Sep 9, 2025, 16:22 PM -
Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials
Sep 9, 2025, 16:22 PM -
Determinants of Willingness to Pay Thresholds in NICE Oncology Technology Appraisals
Sep 9, 2025, 16:22 PM -
Systematic Review of Decision-Analytic Models Estimating the Economic Impact of Prescription Opioid Use and Associated Adverse Events
Sep 9, 2025, 16:22 PM -
Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of High-Dose Trivalent Influenza Vaccine in the Elderly: A Cohort-Based Economic Model From the Italian NHS Perspective
Sep 9, 2025, 16:22 PM -
Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Hyaluronic Acid Viscosupplementation for Knee Osteoarthritis in Colombia
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction
Sep 9, 2025, 16:22 PM -
Assessing the Feasibility of the Implementation of a Subscription Model Pricing Solution Aimed at Broadening Access to All Eligible Patients Within the HER2 Indication
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 2 Diabetes Using Insulin in Sweden: A National Real-World Evidence Perspective
Sep 9, 2025, 16:22 PM -
To What Endpoint? Exploring Clinical Outcome Assessments of Pain in Phase 2 and 3 Trials and Drug Labels in Women’s Health Conditions
Sep 9, 2025, 16:22 PM -
When Trials Don’t Meet: A Retrospective Statistical Analysis Using Matching-Adjusted Indirect Comparison (MAIC) and Individual Patient Data (IPD) to Compare Catiolanze® With Other Preservative-Free (PF) Latanoprost in Open-Angle Glaucoma (OAG)
Sep 9, 2025, 16:22 PM -
Do Public Preferences Matter? Health-Economic Evaluation of Antineoplastic Medication Considering EQ-5D Value Sets From Several Countries
Sep 9, 2025, 16:22 PM -
Long-Term Impact of Emicizumab in Hemophilia A (HA): Analysis by Inhibitor Status in Three Latin American (LATAM) Countries
Sep 9, 2025, 16:22 PM
